{"id":"https://openalex.org/W2007309846","doi":"https://doi.org/10.1097/qad.0b013e328310407e","title":"Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults","display_name":"Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults","publication_year":2008,"publication_date":"2008-10-02","ids":{"openalex":"https://openalex.org/W2007309846","doi":"https://doi.org/10.1097/qad.0b013e328310407e","mag":"2007309846","pmid":"https://pubmed.ncbi.nlm.nih.gov/18832875","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2659649"},"language":"en","primary_location":{"id":"doi:10.1097/qad.0b013e328310407e","doi":"https://doi.org/10.1097/qad.0b013e328310407e","is_oa":false,"landing_page_url":"https://doi.org/10.1097/qad.0b013e328310407e","pdf_url":null,"source":{"id":"https://openalex.org/S20605092","display_name":"AIDS","issn_l":"0269-9370","issn":["0269-9370","1473-5571"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2659649","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021611829","display_name":"Jean Bisimwa Nachega","orcid":"https://orcid.org/0000-0002-2862-4443","observed_orcids":["https://orcid.org/0000-0002-2862-4443"]},"institutions":[{"id":"https://openalex.org/I26092322","display_name":"Stellenbosch University","ror":"https://ror.org/05bk57929","country_code":"ZA","type":"education","lineage":["https://openalex.org/I26092322"]}],"countries":["ZA"],"is_corresponding":true,"raw_author_name":"Jean B Nachega","raw_affiliation_strings":["Department of Internal Medicine and Center for Infectious Disease, Stellenbosch University, Cape Town, South Africa. jnachega@sun.ac.za","Department of Internal Medicine and Center for Infectious Disease, Stellenbosch University, Cape Town, South Africa","to Professor Jean B. Nachega, MD, PhD, Director, Center for Infectious Diseases, Faculty of Health Sciences, Stellenbosch University, Teaching Building, 5th Floor, Room 5012, Tygerberg Campus, Cape Town, South Africa. E-mail: [email\u00a0protected] or [email\u00a0protected]"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine and Center for Infectious Disease, Stellenbosch University, Cape Town, South Africa. jnachega@sun.ac.za","institution_ids":["https://openalex.org/I26092322"]},{"raw_affiliation_string":"Department of Internal Medicine and Center for Infectious Disease, Stellenbosch University, Cape Town, South Africa","institution_ids":["https://openalex.org/I26092322"]},{"raw_affiliation_string":"to Professor Jean B. Nachega, MD, PhD, Director, Center for Infectious Diseases, Faculty of Health Sciences, Stellenbosch University, Teaching Building, 5th Floor, Room 5012, Tygerberg Campus, Cape Town, South Africa. E-mail: [email\u00a0protected] or [email\u00a0protected]","institution_ids":["https://openalex.org/I26092322"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113862539","display_name":"Michael Hislop","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Hislop","raw_affiliation_strings":["Aid for AIDS Disease Management Program Ltd., Cape Town, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Aid for AIDS Disease Management Program Ltd., Cape Town, South Africa","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066677332","display_name":"David W. Dowdy","orcid":"https://orcid.org/0000-0003-0481-7475","observed_orcids":["https://orcid.org/0000-0003-0481-7475"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David W Dowdy","raw_affiliation_strings":["Department of Epidemiology, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Epidemiology, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048477426","display_name":"Joel E. Gallant","orcid":"https://orcid.org/0000-0002-7144-1642","observed_orcids":["https://orcid.org/0000-0002-7144-1642"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joel E Gallant","raw_affiliation_strings":["Department of Epidemiology, USA","Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Epidemiology, USA","institution_ids":[]},{"raw_affiliation_string":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA","institution_ids":["https://openalex.org/I145311948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071106707","display_name":"Richard E. Chaisson","orcid":"https://orcid.org/0000-0003-4710-925X","observed_orcids":["https://orcid.org/0000-0003-4710-925X"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard E Chaisson","raw_affiliation_strings":["Department of Epidemiology, USA","Department of International Health, Johns Hopkins Bloomberg School of Public Health Global Disease Epidemiology and Control Program, Baltimore, Maryland, USA","Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Epidemiology, USA","institution_ids":[]},{"raw_affiliation_string":"Department of International Health, Johns Hopkins Bloomberg School of Public Health Global Disease Epidemiology and Control Program, Baltimore, Maryland, USA","institution_ids":["https://openalex.org/I145311948"]},{"raw_affiliation_string":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA","institution_ids":["https://openalex.org/I145311948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063522427","display_name":"Leon Regensberg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Leon Regensberg","raw_affiliation_strings":["Aid for AIDS Disease Management Program Ltd., Cape Town, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Aid for AIDS Disease Management Program Ltd., Cape Town, South Africa","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5034322602","display_name":"Gary Maartens","orcid":"https://orcid.org/0000-0003-3080-6606","observed_orcids":["https://orcid.org/0000-0003-3080-6606"]},"institutions":[{"id":"https://openalex.org/I157614274","display_name":"University of Cape Town","ror":"https://ror.org/03p74gp79","country_code":"ZA","type":"education","lineage":["https://openalex.org/I157614274"]},{"id":"https://openalex.org/I2802258008","display_name":"Groote Schuur Hospital","ror":"https://ror.org/00c879s84","country_code":"ZA","type":"healthcare","lineage":["https://openalex.org/I1307091933","https://openalex.org/I2802258008"]}],"countries":["ZA"],"is_corresponding":false,"raw_author_name":"Gary Maartens","raw_affiliation_strings":["Department of Medicine, Division of Clinical Pharmacology, Groote Schuur Hospital, University of Cape Town, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Clinical Pharmacology, Groote Schuur Hospital, University of Cape Town, South Africa","institution_ids":["https://openalex.org/I157614274","https://openalex.org/I2802258008"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5021611829"],"corresponding_institution_ids":["https://openalex.org/I26092322"],"apc_list":null,"apc_paid":null,"fwci":5.3565,"has_fulltext":false,"cited_by_count":78,"citation_normalized_percentile":{"value":0.95612493,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"22","issue":"16","first_page":"2117","last_page":"2125"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.8955000042915344,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.8955000042915344,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.10170000046491623,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/efavirenz","display_name":"efavirenz","score":0.9150000214576721},{"id":"https://openalex.org/keywords/nevirapine","display_name":"nevirapine","score":1.0},{"id":"https://openalex.org/keywords/hiv-infection","display_name":"HIV infection","score":0.7559999823570251},{"id":"https://openalex.org/keywords/initial-antiretroviral-therapy","display_name":"initial antiretroviral therapy","score":0.9480000138282776},{"id":"https://openalex.org/keywords/highly-active-antiretroviral-therapy","display_name":"highly active antiretroviral therapy","score":0.906000018119812},{"id":"https://openalex.org/keywords/virologic-failure","display_name":"virological failure","score":0.9129999876022339},{"id":"https://openalex.org/keywords/antiretroviral-therapy-adherence","display_name":"antiretroviral therapy adherence","score":0.8119999766349792},{"id":"https://openalex.org/keywords/all-cause-mortality","display_name":"all-cause mortality","score":0.8339999914169312},{"id":"https://openalex.org/keywords/drug-switching","display_name":"drug switching","score":0.5870000123977661},{"id":"https://openalex.org/keywords/viral-suppression","display_name":"viral suppression","score":0.6880000233650208},{"id":"https://openalex.org/keywords/southern-africa","display_name":"Southern Africa","score":0.6800000071525574},{"id":"https://openalex.org/keywords/sub-saharan-africa","display_name":"sub-Saharan Africa","score":0.7850000262260437},{"id":"https://openalex.org/keywords/adults","display_name":"adults","score":0.5180000066757202},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.4269999861717224}],"concepts":[{"id":"https://openalex.org/C2779130552","wikidata":"https://www.wikidata.org/wiki/Q263713","display_name":"Nevirapine","level":5,"score":0.9626819491386414},{"id":"https://openalex.org/C2781432083","wikidata":"https://www.wikidata.org/wiki/Q422645","display_name":"Efavirenz","level":5,"score":0.9223857522010803},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.8003395795822144},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.7359495759010315},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7057602405548096},{"id":"https://openalex.org/C119060515","wikidata":"https://www.wikidata.org/wiki/Q1916617","display_name":"Interquartile range","level":2,"score":0.7051439881324768},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6046068668365479},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.541439414024353},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.5358157753944397},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.4824393689632416},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.46686530113220215},{"id":"https://openalex.org/C2777351918","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Reverse-transcriptase inhibitor","level":5,"score":0.4283475875854492},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2377971112728119},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.17390933632850647},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.15884113311767578}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000353","descriptor_name":"Africa, Southern","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D000480","descriptor_name":"Alkynes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003521","descriptor_name":"Cyclopropanes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004341","descriptor_name":"Drug Evaluation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010349","descriptor_name":"Patient Compliance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000302","qualifier_name":"isolation & purification","is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017211","descriptor_name":"Treatment Failure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018791","descriptor_name":"CD4 Lymphocyte Count","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019562","descriptor_name":"Viral Load","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019829","descriptor_name":"Nevirapine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D023241","descriptor_name":"Antiretroviral Therapy, Highly Active","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D048588","descriptor_name":"Benzoxazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1097/qad.0b013e328310407e","doi":"https://doi.org/10.1097/qad.0b013e328310407e","is_oa":false,"landing_page_url":"https://doi.org/10.1097/qad.0b013e328310407e","pdf_url":null,"source":{"id":"https://openalex.org/S20605092","display_name":"AIDS","issn_l":"0269-9370","issn":["0269-9370","1473-5571"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS","raw_type":"journal-article"},{"id":"pmid:18832875","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18832875","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS (London, England)","raw_type":"Comparative Study"},{"id":"pmh:oai:pubmedcentral.nih.gov:2659649","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2659649","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"AIDS","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:2659649","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2659649","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"AIDS","raw_type":"Text"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.7900000214576721,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[{"id":"https://openalex.org/G148266931","display_name":"Underlying mechanisms of schistosome/snail compatibility","funder_award_id":"R01AI016137","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G2142176442","display_name":"Medical Scientist Training Program","funder_award_id":"T32GM007309","funder_id":"https://openalex.org/F4320337354","funder_display_name":"National Institute of General Medical Sciences"},{"id":"https://openalex.org/G2173311696","display_name":null,"funder_award_id":"K23 AI068582","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G418378056","display_name":"DOT-HARRT for HIV-Infected South African Adults","funder_award_id":"5k23ai068582-05","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G4753355891","display_name":null,"funder_award_id":"AI5535901","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G6340998055","display_name":null,"funder_award_id":"AI 016137","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G6997000463","display_name":"Underlying mechanisms of schistosome/snail compatibility","funder_award_id":"R21AI016137","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G7860048315","display_name":null,"funder_award_id":"5 T32 GMO7309","funder_id":"https://openalex.org/F4320332505","funder_display_name":"U.S. Public Health Service"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332505","display_name":"U.S. Public Health Service","ror":"https://ror.org/05xf94514"},{"id":"https://openalex.org/F4320337354","display_name":"National Institute of General Medical Sciences","ror":"https://ror.org/04q48ey07"},{"id":"https://openalex.org/F4320337355","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W1516893700","https://openalex.org/W1964020548","https://openalex.org/W1965576725","https://openalex.org/W1967049051","https://openalex.org/W1971285141","https://openalex.org/W1978540833","https://openalex.org/W1980520085","https://openalex.org/W1991864115","https://openalex.org/W2015338056","https://openalex.org/W2016257631","https://openalex.org/W2022649583","https://openalex.org/W2025689551","https://openalex.org/W2037561002","https://openalex.org/W2042085468","https://openalex.org/W2047734031","https://openalex.org/W2050055289","https://openalex.org/W2052236736","https://openalex.org/W2054022938","https://openalex.org/W2056779298","https://openalex.org/W2057112394","https://openalex.org/W2122280827","https://openalex.org/W2131329205","https://openalex.org/W2132801707","https://openalex.org/W2133166320","https://openalex.org/W2135680761","https://openalex.org/W2141776019","https://openalex.org/W2156330207","https://openalex.org/W2183940924","https://openalex.org/W2318545861","https://openalex.org/W2321852728"],"related_works":["https://openalex.org/W2038756830","https://openalex.org/W1607406129","https://openalex.org/W7099424276","https://openalex.org/W2078653938","https://openalex.org/W1978163816","https://openalex.org/W2142053349","https://openalex.org/W1997321745","https://openalex.org/W2028029127","https://openalex.org/W1967527569","https://openalex.org/W1999992655"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"determine":[2],"the":[3,249],"effectiveness":[4],"of":[5,57,70,92,159],"efavirenz":[6,95,122,183,192,233,246],"versus":[7,132,142],"nevirapine":[8,93,113,155,181,194],"in":[9,16,54,196,255],"initial":[10,227],"antiretroviral":[11,31,41,230],"therapy":[12,42,231],"regimens":[13],"for":[14],"adults":[15,33],"sub-Saharan":[17],"Africa.":[18,59],"DESIGN:":[19],"Observational":[20],"cohort":[21],"study.":[22],"METHODS:":[23],"Study":[24],"participants":[25],"were":[26,114],"2817":[27],"HIV-infected,":[28],"highly":[29,39,228],"active":[30,40,229],"therapy-naive":[32],"who":[34],"began":[35],"nevirapine-based":[36],"or":[37,94,137],"efavirenz-based":[38],"between":[43],"January":[44],"1998":[45],"and":[46,90,174,209,239,262],"September":[47],"2004":[48],"via":[49],"a":[50,150],"private-sector":[51],"HIV/AIDS":[52],"program":[53],"nine":[55],"countries":[56],"southern":[58],"The":[60,100],"primary":[61],"outcome":[62],"was":[63,104,234],"time":[64,80,199,211],"to":[65,81,123,182,193,200,212,268],"virologic":[66,97,160,187,238],"failure":[67,161,213],"(two":[68],"measurements":[69],"viral":[71,82],"loads":[72],">or=400":[73],"copies/ml).":[74],"Secondary":[75],"outcomes":[76,241],"included":[77],"all-cause":[78],"mortality,":[79],"load":[83],"less":[84,116],"than":[85,118,139,221,242],"400":[86],"copies/ml,":[87],"pharmacy-claim":[88,147],"adherence,":[89,126],"discontinuation":[91,176],"without":[96],"failure.":[98],"RESULTS:":[99],"median":[101],"follow-up":[102],"period":[103],"2.0":[105],"years":[106],"(interquartile":[107],"range":[108],"1.2-2.6).":[109],"Patients":[110],"started":[111,120],"on":[112,121,154,223],"significantly":[115,197],"likely":[117],"those":[119],"achieve":[124],"high":[125],"whether":[127],"defined":[128],"as":[129],"100%":[130],"(30.2":[131],"38.1%,":[133],"P":[134,144],"<":[135,145],"0.002)":[136],"more":[138],"90%":[140],"(44.8":[141],"49.4%,":[143],"0.02)":[146],"adherence.":[148],"In":[149,226],"multivariate":[151],"analysis,":[152],"patients":[153],"had":[156,184],"greater":[157],"risk":[158],"[hazard":[162],"ratio":[163,203,215],"(HR":[164],"1.52;":[165],"95%":[166,205,217],"confidence":[167,206,218],"interval":[168,207,219],"(CI)":[169],"1.24-1.86)],":[170],"death":[171],"(2.17;":[172],"1.31-3.60),":[173],"regimen":[175],"(1.67;":[177],"1.32-2.11).":[178],"Switching":[179],"from":[180,191],"no":[185],"significant":[186],"effect,":[188],"whereas":[189],"switching":[190],"resulted":[195],"slower":[198],"suppression":[201],"(hazard":[202,214],"0.58,":[204],"0.35-0.93)":[208],"faster":[210],"3.92;":[216],"1.61-9.55)":[220],"remaining":[222],"efavirenz.":[224],"CONCLUSION:":[225],"regimens,":[232],"associated":[235],"with":[236],"superior":[237],"clinical":[240],"nevirapine,":[243],"suggesting":[244],"that":[245],"might":[247],"be":[248],"preferred":[250],"nonnucleoside":[251],"reverse":[252],"transcriptase":[253],"inhibitor":[254],"resource-limited":[256],"settings.":[257],"However,":[258],"its":[259],"higher":[260],"cost":[261],"potential":[263],"teratogenicity":[264],"are":[265],"important":[266],"barriers":[267],"implementation.":[269]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":10}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}